EnGen Bio
Private Company
Total funding raised: $4.2M
Overview
EnGen Bio is a preclinical-stage biotech developing a universal Type A influenza vaccine and antibody therapy targeting a novel, highly conserved epitope on the M1 matrix protein. The company has generated promising preclinical data demonstrating broad neutralization and protection in animal models, supported by a foundational IP portfolio of nine patents. While still early-stage, its technology addresses a significant unmet need for pandemic preparedness and seasonal flu, attracting interest and funding from major government and philanthropic organizations.
Technology Platform
Platform based on a novel, conserved epitope on the influenza M1 matrix protein for developing universal Type A influenza vaccines and therapeutic antibodies.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
The universal influenza vaccine space is competitive, with numerous biotechs and large pharma companies (e.g., Moderna, Pfizer, GSK) exploring various platforms like mRNA, nanoparticle, and other conserved targets like HA stalk. EnGen Bio's differentiation lies in its unique M1 epitope target, but it must demonstrate superior efficacy or safety to gain market share.